Polish medtech company Medicalgorithmics, listed on the Warsaw Stock Exchange, has signed a significant agreement with CardioScan, a global leader in cardiac diagnostics operating across North America, Asia, Oceania, and Europe. Under the partnership, Medicalgorithmics’ DeepRhythm Platform (DRP) and its AI-based algorithms, DeepRhythmAI (DRAI), will become available to CardioScan clients once the integration process is completed and necessary regulatory approvals are secured. This marks Medicalgorithmics’ second contract in Australia and the twelfth agreement signed by the company in 2025.
Founded by Associate Professor Harry Mond, a world-renowned expert in ECG interpretation and Holter monitoring, CardioScan has over 40 years of experience and has conducted more than 20 million cardiac tests globally. The partnership highlights the cutting-edge innovation and quality of Medicalgorithmics’ AI technology and diagnostic software.
“Signing a contract with CardioScan is a major milestone for us due to the company’s global reputation, dynamic growth, and operational scale,” said Dr. Kris Siemionow, CEO of Medicalgorithmics. “CardioScan is one of the largest cardiac diagnostic service providers worldwide, operating within the international IDTF model. We believe that the results of the DRAI Martini study, published earlier this year in Nature Medicine, which confirmed the high effectiveness and quality of our AI algorithms, will translate into growing interest in our technology. We expect further growth in our share of the global ECG diagnostics market.”
“Following our successful transformation—which involved decoupling our software from Holter devices and opening up to third-party integrations—we’re now consistently executing a strategy of dynamic expansion,” added Jarosław Jerzakowski, COO of Medicalgorithmics. “We’re signing more contracts, especially for our innovative algorithms and software, and this reflects how far we’ve come. Today, we’re in a completely different position than just a few years ago.”
Strong Growth in 2025
The year 2025 has brought a significant increase in global interest in Medicalgorithmics’ products and a rapid pace of new client acquisitions. Since the beginning of the year, the company has signed 12 new agreements with partners from the USA, Canada, Australia, South Korea, Turkey, and other European countries. By comparison, in all of 2024, the company secured 13 new clients in total.
The company also continues to scale its ECG testing operations, reaching 92,000 tests in Q1 2025—representing a year-over-year increase of nearly 100%.
Source: ManagerPlus.pl – Medicalgorithmics signs another deal in Australia: CardioScan bets on Polish AI
